CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
04/26/2022
Back to search
Official data from USPTO
NEUWAY
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
NEUWAY
ST13
US500000088278750Class
1, 5, 40, 42
Filing
88278750
Registration
6466029
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
52
Latest update
04/26/2022
Trademark type
Word
Nice classes
1, 5, 40, 42
Filing date
01/28/2019
Registration date
08/31/2021
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/31/2021
Last transaction
08/31/2021
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
Drawing code
4
Owner type
99
Owner location
Bonn, DE
Examiner
MIZELLE HOWARD, DEZMONA JULYE
Law office
M10
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
NEUWAY Pharma GmbH
Representatives
LEIGH ANN LINDQUIST SUGHRUE MION, PLLC
Technical classification
Nice Classes
Class 1Class 5Class 40Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemicalbiologicalbiochemical and biotechnological products and preparationsnamely small moleculesbiologicsnucleic acidsproteinslipidspolysaccharidesenzymesantibodiescellsmicroorganisms as well as fragmentsfractions and derivatives thereof for laboratory or research use and manufacturing use
Class 5
Chemicalbiologicalbiochemical and biotechnological products and preparations for medicalveterinary and pharmaceutical purposesfor the prevention and treatment of neurologicalneurodegenerativepsychiatricimmune system relatedmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinaryurologicalgynecologicalreproductiveoncologicalhepatologicalophthalmicrespiratorygastrointestinalhormonaldermatologicallymphaticinflammatoryinfectioushematologicalrenalgeneticbacterial and viral diseasessexual dysfunction and pain as well as for gene therapyvaccination or immunostimmulationnamely small moleculesbiologicsnucleic acidsproteinslipidspolysaccharidesenzymesantibodiescellsmicroorganisms as well as fragmentsfractions and derivatives thereof; diagnostic preparations for medical and veterinary use; medicinal preparationspharmaceutical preparations and pharmaceutical substances for the prevention and treatment of neurologicalneurodegenerativepsychiatricimmune system relatedmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinaryurologicalgynecologicalreproductiveoncologicalhepatologicalophthalmicrespiratorygastrointestinalhormonaldermatologicallymphaticinflammatoryinfectioushematologicalrenalgeneticbacterial and viral diseasessexual dysfunction and pain as well as for gene therapyvaccination or immunostimmulation; vaccines; adjuvantscarriers for active ingredientsdrug delivery systems comprising protein based capsids or particles for the release of therapeutic or diagnostic agents for medical use in humans or animals; biological implants comprising active ingredients; drug delivery systems consisting of proteins in the form of capsids or particles; drug delivery systems comprising protein based capsids or particles for the release of therapeutic or diagnostic agents
Class 40
Manufacture of pharmaceutical productsmedicinal productsmedicaments from pharmaceutical compositions for third parties
Class 42
Scientific research and development for othersin particular in the fields of medicinepharmacydiagnosticschemistrybiologybiochemistry and biotechnology; scientific research and development as well as biotechnological services with regard to manufacturing pharmaceutical preparationsactive substance carriersactive substance transport systemsdrug delivery systems and active substance implants for use on humans or animalsfor others; development of pharmaceutical preparationsmedical products for the prevention and treatment of neurologicalneurodegenerativepsychiatricimmune system relatedmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinaryurologicalgynecologicalreproductiveoncologicalhepatologicalophthalmicrespiratorygastrointestinalhormonaldermatologicallymphaticinflammatoryinfectioushematologicalrenalgeneticbacterial and viral diseasessexual dysfunction and pain as well as for gene therapyvaccination or immunostimmulationfor others
Publications
History of USPTO decisions and trademark events.
52 publications found
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/26/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/26/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/26/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
04/26/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
08/31/2021
DP1B
1(B) BASIS DELETED; PROCEED TO REGISTRATION
07/27/2021
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
07/22/2021
IUCN
NOTICE OF ALLOWANCE CANCELLED
07/01/2021
D1BR
TEAS DELETE 1(B) BASIS RECEIVED
07/01/2021
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
06/22/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/27/2021
PUBO
PUBLISHED FOR OPPOSITION
04/27/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/07/2021
OTHE
CASE RETURNED TO EXAMINATION
03/18/2021
IUCN
NOTICE OF ALLOWANCE CANCELLED
03/18/2021
PCBG
PETITION TO DIRECTOR - CHANGE BASIS - GRANTED
10/30/2020
APET
ASSIGNED TO PETITION STAFF
10/29/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
09/26/2020
EX2G
SOU EXTENSION 2 GRANTED
09/24/2020
EXT2
SOU EXTENSION 2 FILED
09/24/2020
EEXT
SOU TEAS EXTENSION RECEIVED
09/24/2020
TPAD
TEAS PETITION TO AMEND BASIS RECEIVED
09/11/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
03/25/2020
EX1G
SOU EXTENSION 1 GRANTED
03/23/2020
EXT1
SOU EXTENSION 1 FILED
03/23/2020
EEXT
SOU TEAS EXTENSION RECEIVED
03/23/2020
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
03/20/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
03/20/2020
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
03/20/2020
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
03/20/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
03/20/2020
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
03/20/2020
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
03/20/2020
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
09/24/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/30/2019
PUBO
PUBLISHED FOR OPPOSITION
07/30/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
07/10/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/24/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/21/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/21/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/21/2019
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
06/12/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
04/12/2019
GNRT
NON-FINAL ACTION E-MAILED
04/12/2019
CNRT
NON-FINAL ACTION WRITTEN
04/12/2019
DOCK
ASSIGNED TO EXAMINER
04/09/2019
AMPX
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
02/25/2019
ALIE
ASSIGNED TO LIE
02/21/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/20/2019
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
02/14/2019
NWAP
NEW APPLICATION ENTERED
01/31/2019
Continuous trademark protection
Get notified about every new filing that threatens NEUWAY or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.